MedTrace Logo

An Integrated Approach to Treating Recurrent Thoracic Carcinomas Resistant to Tyrosine Kinase Inhibitors

NCT02616211 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 15

Last updated 2020-10-19

No results posted yet for this study

Summary

Patients are asked to participate in this study if they have been diagnosed with a thoracic carcinoma which includes lung cancer and have a gene mutation (alteration in the body's genetic instructions) and after undergoing treatment the cancer has come back, progressed, or shown a partial response on standard treatment.

Conditions

  • Adenocarcinoma of Lung
  • Lung Neoplasm
  • Cancer of Lung
  • Lung Cancer
  • Pulmonary Cancer
  • EGFR Genes
  • ALK Genes

Sponsors & Collaborators

  • National Foundation for Cancer Research

    collaborator OTHER

  • Mayo Clinic

    lead OTHER

Principal Investigators

  • Jin Jen, MD, PhD · Mayo Clinic

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-10-31
Primary Completion
2018-10-31
Completion
2019-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02616211 on ClinicalTrials.gov